BioNTech SE
NASDAQ:BNTX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
78.36
124.71
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BNTX stock under the Base Case scenario is 33.33 USD. Compared to the current market price of 113.13 USD, BioNTech SE is Overvalued by 71%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
BioNTech SE
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BNTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
BioNTech SE
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
BioNTech SE, founded in 2008 and headquartered in Mainz, Germany, is a pioneering biotechnology company that has rapidly garnered global attention for its innovative approach to vaccine development and personalized cancer therapies. Originally focused on harnessing the power of messenger RNA (mRNA) technology, BioNTech became a household name following its collaboration with Pfizer to develop one of the first COVID-19 vaccines. This partnership not only showcased the potential of mRNA technology in combatting infectious diseases but also underscored the company’s agility in responding to urgent global health challenges. With its robust pipeline of therapeutics spanning infectious diseases an...
BioNTech SE, founded in 2008 and headquartered in Mainz, Germany, is a pioneering biotechnology company that has rapidly garnered global attention for its innovative approach to vaccine development and personalized cancer therapies. Originally focused on harnessing the power of messenger RNA (mRNA) technology, BioNTech became a household name following its collaboration with Pfizer to develop one of the first COVID-19 vaccines. This partnership not only showcased the potential of mRNA technology in combatting infectious diseases but also underscored the company’s agility in responding to urgent global health challenges. With its robust pipeline of therapeutics spanning infectious diseases and oncology, BioNTech is positioning itself as a leader in the emerging field of immuno-oncology, aiming to harness the body's immune system to fight cancer more effectively.
For investors, BioNTech represents a unique opportunity in the biotech sector, characterized by its strong innovation pipeline, strategic partnerships, and a solid financial footing bolstered by revenues from its COVID-19 vaccine. The company's focus on research and development, with aims to expand its therapeutic offerings beyond infectious diseases to targeted cancer treatments, indicates significant growth potential. Furthermore, as a company driven by science and a commitment to patient-centric solutions, BioNTech is well-positioned to benefit from ongoing advancements in biotechnology and the increasing demand for personalized medicine. With a proven track record and ambitious future aspirations, BioNTech SE offers a compelling narrative for investors looking to capitalize on the transformative potential of biotechnology.
BioNTech SE is a biotechnology company focused on developing and commercializing immunotherapies for various diseases, notably in the field of oncology and infectious diseases. The core business segments of BioNTech can be described as follows:
-
Oncology: This is one of BioNTech's primary focus areas, where it develops personalized cancer therapies using mRNA technology, as well as other platforms like CAR-T cell therapies and checkpoint inhibitors. The aim is to harness the body’s immune system to target and destroy cancer cells.
-
Infectious Diseases: This segment gained significant attention with the development of the COVID-19 vaccine (Comirnaty) in partnership with Pfizer. BioNTech is also exploring mRNA vaccine candidates for other infectious diseases, including influenza and other viral pathogens.
-
Regenerative Medicine: BioNTech is investing in regenerative medicine therapies, which involve using advanced biotherapeutics to repair or replace damaged tissues and organs. This segment is still in the development stage but aims to harness the potential of mRNA for tissue regeneration.
-
Additional Therapeutic Areas: BioNTech is also exploring opportunities in other areas, including autoimmune diseases, where they are leveraging their technology for potential therapies.
-
Partnerships and Collaborations: BioNTech is actively collaborating with other pharmaceutical companies, academic institutions, and research organizations to advance its research and development pipeline. This includes strategic partnerships to enhance discovery and commercialization capabilities.
In summary, BioNTech SE's core business segments are heavily focused on oncology and infectious diseases, with a growing interest in regenerative medicine and autoimmune diseases, supported by various strategic partnerships.
BioNTech SE, a pioneer in the field of messenger RNA (mRNA) technology, possesses several unique competitive advantages over its rivals:
-
Proprietary mRNA Technology: BioNTech’s innovative mRNA platform enables the development of vaccines and therapies that can be rapidly designed and produced. This technology has been pivotal in its success with the COVID-19 vaccine in partnership with Pfizer.
-
Robust R&D Pipeline: The company has a diverse and comprehensive pipeline that extends beyond infectious diseases to include cancer therapeutics and personalized medicine. This allows for multiple revenue streams and reduces reliance on any single product.
-
Strategic Partnerships: BioNTech has established strong partnerships with global pharmaceutical companies, most notably with Pfizer. These collaborations enhance their research capabilities, extend their market reach, and improve financial stability.
-
Strong Intellectual Property Portfolio: The company has developed a robust patent portfolio around its mRNA technology and potential applications, providing it with a competitive edge and barriers to entry for competitors.
-
Experienced Leadership: The founding team, led by Dr. Ugur Sahin and Dr. Ă–zlem TĂĽreci, has extensive experience in biomedical research and drug development, fostering innovation and strategic vision within the company.
-
Regulatory Success: BioNTech has successfully navigated the regulatory landscape, achieving Emergency Use Authorization for its COVID-19 vaccine quickly. This experience can streamline future approvals for new therapies.
-
Manufacturing Capabilities: The company has built efficient manufacturing processes for their mRNA products, allowing for scalability and rapid response to market demands, which is critical in times of health crises.
-
Focus on Personalized Medicine: BioNTech is committed to developing personalized cancer therapies, leveraging its mRNA technology to create tailored treatments that target individual patients’ tumors, distinguishing it from many traditional treatment approaches.
-
Global Reach and Distribution: The partnerships with established pharmaceutical companies enhance BioNTech’s ability to distribute its products globally, increasing its market presence and accessibility.
-
Strong Financial Position: BioNTech has recorded significant revenues from its COVID-19 vaccine, allowing it to reinvest in R&D and expansion, further solidifying its competitive position.
These advantages create a solid foundation for BioNTech to sustain its competitive edge in the rapidly evolving biotechnology landscape.
BioNTech SE, a biotechnology company known for its innovative mRNA technology and its role in developing COVID-19 vaccines, faces several risks and challenges in the near future. Here are some key areas of concern:
-
Market Competition: The biotechnology and pharmaceutical sectors are highly competitive. BioNTech faces competition from other vaccine manufacturers and emerging biotech firms working on similar technologies. The development of next-generation vaccines or therapeutics by competitors could impact BioNTech's market share.
-
Regulatory Challenges: Navigating the regulatory landscape can be complex. Any delays or rejections in the approval process for new products could affect the company's pipeline and market potential. Additionally, changes in regulations or policies can create uncertainty.
-
Evolving COVID-19 Market: The COVID-19 vaccine market is evolving, with changing demand as populations become vaccinated and booster shots become common. If demand decreases or if mRNA technology becomes less favored due to emerging variants, BioNTech's revenues might be negatively affected.
-
Dependence on Partnerships: BioNTech has significant partnerships with companies like Pfizer and has collaborated with various research institutions. An adverse change in these partnerships or a failure to secure favorable collaborations could impact its research and development capabilities.
-
Intellectual Property Risks: As a biotechnology company, protecting its intellectual property is crucial. There could be risks related to patent infringements or challenges from competitors, which could undermine its competitive advantage.
-
Supply Chain Disruptions: The global supply chain has faced disruptions due to various factors, including the pandemic, geopolitical tensions, and trade issues. Any disruption in the supply chain for raw materials or distribution channels can affect production timelines and costs.
-
Public Sentiment and Vaccine Hesitancy: Vaccine hesitancy and changing public perceptions about COVID-19 and vaccines can impact the uptake of BioNTech's products. Negative media coverage or public perception can also affect investor sentiment and funding opportunities.
-
Financial Sustainability: While BioNTech has seen substantial revenues from its COVID-19 vaccine, the company must continue to innovate and diversify its product pipeline to ensure long-term financial sustainability. Reliance on a single product or income source can create vulnerabilities.
-
Research and Development Risks: The inherent risks in R&D include failures in clinical trials and unforeseen challenges in developing new therapies or vaccines. High investments in R&D might not always translate to successful product launches.
-
Geopolitical Risks: Geopolitical tensions and policies can impact BioNTech's ability to operate internationally. Changes in trade agreements or sanctions can affect its supply chain and market access.
By staying informed about these risks and challenges, BioNTech SE can better prepare and strategize to navigate the changing landscape of the biotechnology industry.
Revenue & Expenses Breakdown
BioNTech SE
Balance Sheet Decomposition
BioNTech SE
Current Assets | 18.3B |
Cash & Short-Term Investments | 17.3B |
Receivables | 286.5m |
Other Current Assets | 699.4m |
Non-Current Assets | 4B |
Long-Term Investments | 1.4B |
PP&E | 1.1B |
Intangibles | 1.2B |
Other Non-Current Assets | 210.5m |
Current Liabilities | 2.4B |
Accounts Payable | 881.5m |
Other Current Liabilities | 1.5B |
Non-Current Liabilities | 739.7m |
Long-Term Debt | 219.3m |
Other Non-Current Liabilities | 520.4m |
Earnings Waterfall
BioNTech SE
Revenue
|
2.7B
EUR
|
Cost of Revenue
|
-396.2m
EUR
|
Gross Profit
|
2.3B
EUR
|
Operating Expenses
|
-3B
EUR
|
Operating Income
|
-733.3m
EUR
|
Other Expenses
|
228.9m
EUR
|
Net Income
|
-504.4m
EUR
|
Free Cash Flow Analysis
BioNTech SE
EUR | |
Free Cash Flow | EUR |
In Q3 2024, BioNTech reported revenues of EUR 1.245 billion, a rise from EUR 895 million in Q3 2023, primarily driven by early COVID-19 vaccine approvals. The company posted a net income of EUR 198 million and diluted EPS of EUR 0.81. Despite robust revenues, BioNTech anticipates a loss for the full year and has adjusted SG&A expense guidance down to EUR 600-700 million, reducing capital expenditure guidance to EUR 300-400 million. Their oncology pipeline, highlighted by the promising BNT327 antibody, is poised for multiple product launches by 2030, demonstrating a 74% objective response rate in trials for triple-negative breast cancer.
What is Earnings Call?
BNTX Profitability Score
Profitability Due Diligence
BioNTech SE's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
BioNTech SE's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
BNTX Solvency Score
Solvency Due Diligence
BioNTech SE's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
BioNTech SE's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNTX Price Targets Summary
BioNTech SE
According to Wall Street analysts, the average 1-year price target for BNTX is 138.68 USD with a low forecast of 100.23 USD and a high forecast of 179.55 USD.
Dividends
Current shareholder yield for BNTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 3,082 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The company develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one BNTX stock under the Base Case scenario is 33.33 USD.
Compared to the current market price of 113.13 USD, BioNTech SE is Overvalued by 71%.